Lucence Diagnostics, a genomic medicine company focused on inventing advanced cancer diagnostics, and Singapore Diagnostics (Philippines), the largest pure clinical laboratory in the country, announced today a partnership to market Lucence’s advanced cancer blood tests in the Philippines.
Singapore Diagnostics will distribute Lucence’s range of blood tests for cancer diagnosis and treatment in the Philippines. The blood tests are based on Lucence’s patented liquid biopsy technology, which detect genetic mutations from tumor DNA circulating in the blood. This allows doctors to select the most appropriate cancer treatment according to the genetic mutations identified.
Compared to conventional tissue biopsy, Lucence’s liquid biopsy approach is non-invasive and faster. The tests target the most common cancers in Asia like breast, colon, lung and nasopharyngeal cancer.
Lucence’s blood tests can also diagnose early stage nasopharyngeal cancer before symptoms show and check whether a person is predisposed to cancer by detecting genes commonly associated with increased risk of cancer.
According to the Philippine Statistics Authority, one out of every 10 deaths in the country is caused by cancer. Singapore Diagnostics is one the largest laboratories in the Philippines handling 200,000 tests every month. It is part of a group of regional laboratories operating in Singapore, Malaysia and Hong Kong. Singapore Diagnostics currently serves 500 hospital and clinic laboratory sites in Metro Manila. With this partnership, Lucence’s cancer blood tests will now be made available to all its customers in the Philippines.
“We are delighted to work with Lucence to provide their advanced cancer blood tests in the Philippines. Singapore Diagnostics always strives to be at the forefront of innovation in our industry by seeking out the latest medical technologies and exploring its applications in clinical settings. Through our partnership with Lucence, we can now provide the most advanced technology for cancer detection and treatment to our customers. We look forward to working closely with Lucence to drive better cancer care in the Philippines,” said Mr. Ritche Evidente, CEO, Singapore Diagnostics.
“Lucence is excited to collaborate with Singapore Diagnostics to make available our cancer blood tests in the Philippines. We are committed to reducing preventable cancer deaths through early detection and optimal treatment selection. With Singapore Diagnostics’ extensive customer network, we hope to help improve the diagnosis and treatment of cancer in Philippines to save lives earlier,” said Dr. Min-Han Tan, Founder and CEO, Lucence Diagnostics.
For more information, please contact:
About Lucence Diagnostics
Lucence Diagnostics is a genomic medicine company focused on inventing advanced cancer diagnostics to improve cancer care. Headquartered in Singapore with offices in Hong Kong and the US, Lucence invents genetic tests that enable earlier cancer diagnosis and better treatment selections. Lucence’s tests target the most common cancers in the world based on its patented sequencing technology and in-house clinical analytics. Its key operations are supported by an ISO15189 accredited molecular diagnostics laboratory and a clinical cancer genetics medical center.
For more information, please visit www.lucencedx.com.
About Singapore Diagnostics
Singapore Diagnostics is among the Philippines’ largest laboratories handling 200,000 tests per month. Since 2013, Singapore Diagnostics has developed an extensive logistical and customer network: currently serving 500 hospital and clinic laboratory sites in and around Metro Manila. It is the only laboratory in the Philippines with all tests fully enrolled and tested for proficiency under the Royal College of Pathologists of Australasia (RCPA) and the College of American Pathologists (CAP).
For more information, please visit www.singaporediagnostics.com.